In this online CME self-learning program:
Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers, and its incidence has risen from the lower end of 22,000 cases per year five years ago to an estimated 26,850 in 2015; mortality rates have stayed consistent at approximately 11,000 per year. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.
Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM. Moreover, professional guidelines are updated with frequency, and communicating related information to healthcare professionals in a timely manner is a demonstrated need. The literature suggests that practicing healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming.
Faculty introduction, disclosures
Introduction content: cursory refresher and review
Updates in treatment in patients with MM
Summary, conclusions, and best practice recap
Health professionals specializing in: hematology, oncology, and healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with MM.
This program is supported by an educational grant from AMGEN
Release Date: August 29, 2016 -- Expiration Date: August 29, 2018
Faculty: Dimitrios Tzachanis, MD, PhD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dimitrios Tzachanis, M.D., Ph.D., Assistant Clinical Professor of Medicine, University of California San Diego, La Jolla, CA has no relevant financial disclosures to report.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from AMGEN
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy
Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices
Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation
Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation